- CONTACT US
- AFS
- Business
- Bussiness
- Car
- Career
- Celebrity
- Digital Products
- Education
- Entertainment
- Fashion
- Film
- Food
- Games
- General Health
- Health
- Health Awareness
- Healthy
- Healthy Lifestyle
- History Facts
- Household Appliances
- Internet
- Investment
- Law
- Lifestyle
- Loans&Mortgages
- Luxury Life Style
- movie
- Music
- Nature
- News
- Opinion
- Pet
- Plant
- Politics
- Recommends
- Science
- Self-care
- services
- Smart Phone
- Sports
- Style
- Technology
- tire
- Travel
- US
- World
Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
How to watch 'A Charlie Brown Christmas' for free this weekend - 2'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- 3Germany's Deutsche Welle broadcaster declared 'undesirable' in Russia
- 49 African migrants died in freezing temperatures near Morocco-Algeria border
- 5'No middle ground' for tackling antisemitism after Bondi Beach mass shooting, deputy FM Haskel says
- Doritos and Cheetos dial back the bright orange in new versions without artificial ingredients
- Seven deaths possibly linked to malfunctioning glucose monitors
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- The cheap health insurance promoted by Trump officials has this catch
- Bombardier Global 8000 Enters Service
- Novo Nordisk gears up for December Ozempic launch in India, sources say
- US FDA approves Kura-Kyowa's blood cancer therapy
- Analysis-From 'Icarus bug' to flawed panels: Airbus counts cost of relying on single model
- Consumers advised to dispose of 19 cooking pans due to lead leaching risk, FDA reports
